Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Market Closed 05-03 16:00:00 EDT

957.00

+19.39

+2.07%

盘后957.00

+0.000.00%

19:29 EDT

High958.13	Low926.94	Vol547.37K
Open926.94	D1 Closing937.61	Amplitude3.33%
Mkt Cap105.04B	Tradable Cap100.49B	Total Shares109.76M
T/O519.93M	T/O Rate0.52%	Tradable Shares105.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":957,"timestamp":1714766400000,"preClose":937.61,"halted":0,"volume":547373,"hourTrading":{"tag":"盘后","latestPrice":957,"preClose":957,"latestTime":"19:29 EDT","volume":34701,"amount":33198321.7388,"timestamp":1714778944142},"delay":0,"floatShares":105000000,"shares":109761896,"eps":34.77,"marketStatus":"Market Closed","change":19.39,"latestTime":"05-03 16:00:00 EDT","open":926.94,"high":958.13,"low":926.94,"amount":519932151.50130004,"amplitude":0.033265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":34.77,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714982400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":937.61,"preHourTrading":{"tag":"盘前","latestPrice":929.79,"preClose":937.61,"latestTime":"09:15 EDT","volume":111,"amount":103156.44474,"timestamp":1714742148559},"postHourTrading":{"tag":"盘后","latestPrice":957,"preClose":957,"latestTime":"19:29 EDT","volume":34701,"amount":33198321.7388,"timestamp":1714778944142},"volumeRatio":0.8621608094680289},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2433481988","title":"Wall Street Breakfast: The Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2433481988","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2433481988?lang=en_us&edition=fundamental","pubTime":"2024-05-05 18:27","pubTimestamp":1714904867,"startTime":"0","endTime":"0","summary":"Listen on the go!","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458971009/image_458971009.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458971009/image_458971009.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4689591-wall-street-breakfast-week-ahead","is_publish_highlight":false,"gpt_icon":0},{"id":"2432146554","title":"Eyes On Apple, Uber, Disney, Rivian And Coupang","url":"https://stock-news.laohu8.com/highlight/detail?id=2432146554","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432146554?lang=en_us&edition=fundamental","pubTime":"2024-05-04 22:00","pubTimestamp":1714831200,"startTime":"0","endTime":"0","summary":"Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688679-eyes-on-apple-uber-disney-rivian-and-coupang","is_publish_highlight":false,"gpt_icon":0},{"id":"2432718143","title":"Amgen Could Become A Real Contender In The Obesity Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2432718143","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432718143?lang=en_us&edition=fundamental","pubTime":"2024-05-04 21:13","pubTimestamp":1714828382,"startTime":"0","endTime":"0","summary":"Amgen's shares surged after management's earnings call comments about the phase 2 trial of obesity candidate MariTide.These comments and previous phase 2 data point to the increasing possibility of Am","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4689415-amgen-could-become-real-contender-obesity-market","is_publish_highlight":false,"gpt_icon":0},{"id":"2432112780","title":"23 Most Profitable Stocks of the Last 12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2432112780","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2432112780?lang=en_us&edition=fundamental","pubTime":"2024-05-04 19:38","pubTimestamp":1714822698,"startTime":"0","endTime":"0","summary":"In this article, we discuss the 23 most profitable stocks of the last 12 months. If you want to skip our detailed analysis of these stocks, go directly to 5 Most Profitable Stocks of the Last 12 Months.The fortunes of these firms are set to rise even further as AI hype and rate cut expectations serve to increase interest in growth stocks. Businesses are investing heavily in AI tools to keep pace with industry demand in this regard. Satya Nadella, the CEO of Microsoft Corporation , recently highlighted the role that he expected AI to play in changing work trends in the coming years and months. He made these comments during the second quarter earnings call at the end of January.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hh4AeuW1u1Op2lw6i0kj3g--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/52eb8f614e287a68df5375883bb318f1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hh4AeuW1u1Op2lw6i0kj3g--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/52eb8f614e287a68df5375883bb318f1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/23-most-profitable-stocks-last-113818389.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2432182201","title":"Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2432182201","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2432182201?lang=en_us&edition=fundamental","pubTime":"2024-05-04 02:18","pubTimestamp":1714760293,"startTime":"0","endTime":"0","summary":"The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/shhh-3-secret-gene-editing-stocks-flying-below-wall-streets-radar/","is_publish_highlight":false,"gpt_icon":0},{"id":"2432901844","title":"Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2432901844","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2432901844?lang=en_us&edition=fundamental","pubTime":"2024-05-03 22:15","pubTimestamp":1714745746,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $9.55 EPS, expectations were $10.17. Regeneron Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter .Operator: Welcome to the Regeneron Pharmaceuticals First Quarter 2024 Earnings Conference Call. My name is Josh, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.Regeneron does not undertake any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. In addition, please note that GAAP and non-GAAP financial measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconci","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jCXZp.ZhWMqygm6VLIkk4w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jCXZp.ZhWMqygm6VLIkk4w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-nasdaq-regn-141546945.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432970158","title":"Regeneron Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2432970158","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432970158?lang=en_us&edition=fundamental","pubTime":"2024-05-03 21:01","pubTimestamp":1714741276,"startTime":"0","endTime":"0","summary":"NasdaqGS:REGN Earnings and Revenue Growth May 3rd 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 2.4%. Earnings per share  also missed analyst estimates by 21%.Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are up 5.3% from a week ago.Be aware that  Regeneron Pharmaceuticals is showing  1 warning sign in our investment analysis that you should know about...","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-first-quarter-2024-130116132.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432494642","title":"Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2432494642","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2432494642?lang=en_us&edition=fundamental","pubTime":"2024-05-03 15:10","pubTimestamp":1714720235,"startTime":"0","endTime":"0","summary":"Revenue: Grew 7% year-over-year to $3.1 billion, excluding COVID antibodies contributions.Net Income: First quarter diluted net income per share was $9.55.Free Cash Flow: Generated $1.4 billion in the first quarter.Market Capitalization: Not directly mentioned, but financial health suggests a robust market cap.Gross Margin: Approximately 89% on net product sales.Sanofi Collaboration Revenue: Significant contributor to revenue growth.Libtayo Global Net Product Sales: Increased by 45%.Dupixent Global Net Product Sales: $3.1 billion, up 24%.Regeneron Pharmaceuticals Inc  reported a solid start to 2024 with a 7% revenue growth year-over-year, excluding last year's revenue from COVID antibodies.Regeneron Pharmaceuticals Inc  received complete response letters from the FDA concerning odronextamab for certain lymphomas, indicating challenges in gaining approval.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-q1-071035938.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432911297","title":"Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight","url":"https://stock-news.laohu8.com/highlight/detail?id=2432911297","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2432911297?lang=en_us&edition=fundamental","pubTime":"2024-05-03 13:08","pubTimestamp":1714712918,"startTime":"0","endTime":"0","summary":"Regeneron showcases robust product sales growth amidst competitive pharmaceutical landscape.Strategic collaborations bolster Regeneron's R&D, presenting both opportunities and financial obligations.Regeneron's innovation in biotechnology positions it well for future growth, despite industry challenges.Comprehensive SWOT analysis reveals Regeneron's potential to navigate the complex biopharma sector.Regeneron Pharmaceuticals Inc , a leader in biotechnology, focuses on developing treatments for eye diseases, cardiovascular conditions, cancer, and inflammation. On May 2, 2024, Regeneron filed its latest 10-Q report, revealing a nuanced financial landscape. The company reported a slight decrease in net income from $817.8 million in Q1 2023 to $722.0 million in Q1 2024, despite a modest increase in net product sales. Collaboration revenue saw a dip, indicating the dynamic nature of its partnerships. Research and development expenses increased, reflecting Regeneron's commitment to innovation","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KfinlKsQvL7zFeLz4fu8og--~B/aD03ODQ7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/6487c7b03557648d221f121bd7d6a335","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KfinlKsQvL7zFeLz4fu8og--~B/aD03ODQ7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/6487c7b03557648d221f121bd7d6a335"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/decoding-regeneron-pharmaceuticals-inc-regn-050838413.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432093008","title":"Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2432093008","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432093008?lang=en_us&edition=fundamental","pubTime":"2024-05-03 03:49","pubTimestamp":1714679385,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/05/38596483/regeneron-pharmaceuticals-targets-quality-weight-loss-in-latest-obesity-innovation","is_publish_highlight":false,"gpt_icon":0},{"id":"2432890889","title":"Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2432890889","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432890889?lang=en_us&edition=fundamental","pubTime":"2024-05-02 22:01","pubTimestamp":1714658460,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. REGN delivered lower-than-expected first-quarter 2024 results due to declining sales of its lead drug, Eylea . The company reported earnings per share  of $9.55, which missed the Zacks Consensus Estimate of $10.20. The company recorded EPS of $10.09 in the year-ago period.Higher expenses and lower revenues adversely impacted the bottom line.Total revenues declined 1% year over year to $3.14 billion, which also missed the Zacks Consensus Estimate of $3.19 billion.Shares are trading down in response to the dismal results.Regeneron’s shares have risen 2.9% year to date against the industry’s decline of 8.8%.Eylea’s sales in the United States declined 16% to $1.2 billion, primarily due to increased competition resulting in lower volumes and a reduced net selling price.Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG BAYRY. Regeneron records net product sales of Eylea in the United States and Bayer does the same outside the c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-regn-q1-earnings-sales-140100800.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432965609","title":"Regeneron Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2432965609","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432965609?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:31","pubTimestamp":1714656718,"startTime":"0","endTime":"0","summary":"* Regeneron Pharmaceuticals Inc    reported quarterly adjusted earnings of $9.55 per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of $10","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432598454","title":"Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say","url":"https://stock-news.laohu8.com/highlight/detail?id=2432598454","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432598454?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:30","pubTimestamp":1714656623,"startTime":"0","endTime":"0","summary":"For the quarter ended March 2024, Regeneron  reported revenue of $3.15 billion, down 0.5% over the same period last year. EPS came in at $9.55, compared to $10.09 in the year-ago quarter.The reported revenue represents a surprise of -1.53% over the Zacks Consensus Estimate of $3.19 billion. With the consensus EPS estimate being $10.20, the EPS surprise was -6.37%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Revenues- Eylea - US: $1.40 billion versus $1.33 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/26ddEdIk.0DefsBmi91u3Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/26ddEdIk.0DefsBmi91u3Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-regn-reports-q1-earnings-133023781.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432353606","title":"4 stocks to watch on Thursday: NVO, AAPL and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2432353606","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432353606?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:11","pubTimestamp":1714655460,"startTime":"0","endTime":"0","summary":"U.S. stock index futures on Thursday pointed to a higher open, a day after the Federal Reserve and chair Jerome Powell were widely perceived to be much more dovish than expected. Here are some stocks ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458727773/image_458727773.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458727773/image_458727773.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098511-4-stocks-to-watch-on-thursday-nvo-aapl-and-more","is_publish_highlight":false,"gpt_icon":0},{"id":"2432670206","title":"Regeneron Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2432670206","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432670206?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:29","pubTimestamp":1714652998,"startTime":"0","endTime":"0","summary":"The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with their 2024 Q1 earnings call.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688439-regeneron-pharmaceuticals-inc-2024-q1-results-earnings-call-presentation","is_publish_highlight":false,"gpt_icon":0},{"id":"2432895603","title":"Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?","url":"https://stock-news.laohu8.com/highlight/detail?id=2432895603","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432895603?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:00","pubTimestamp":1714651222,"startTime":"0","endTime":"0","summary":"It is hard to get excited after looking at Regeneron Pharmaceuticals'  recent performance, when its stock has declined 6.8% over the past month. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. In this article, we decided to focus on Regeneron Pharmaceuticals'  ROE.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Regeneron Pharmaceuticals is:. A Side By Side comparison of Regeneron Pharmaceuticals' Earnings Growth And 15% ROE. Regeneron Pharmaceuticals doesn't pay any regular dividends, meaning that all of its","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weakness-regeneron-pharmaceuticals-inc-nasdaq-120022339.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432729906","title":"Regeneron falls after Q1 miss; announces $3B share buybacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2432729906","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432729906?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:55","pubTimestamp":1714650940,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (NASDAQ:REGN) traded lower in the premarket Thursday despite a newly announced $3B worth of share buybacks as the Eylea maker fell short of Street forecasts with its Q1 2024 ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1129585563/image_1129585563.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1129585563/image_1129585563.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098419-regeneron-stock-falls-despite-3b-buybacks","is_publish_highlight":false,"gpt_icon":0},{"id":"2432652677","title":"Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst Revenue Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2432652677","media":"GuruFocus","top":-1,"share":"https://ttm.financial/m/news/2432652677?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:33","pubTimestamp":1714649620,"startTime":"0","endTime":"0","summary":"On May 2, 2024, Regeneron Pharmaceuticals Inc (REGN, Financial) released its 8-K filing, revealing a mixed financial performance for the first quarter of 2024. The company reported a slight revenue de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2425105/regeneron-pharmaceuticals-inc-regn-q1-2024-earnings-challenges-and-opportunities-amidst-revenue-dip","is_publish_highlight":false,"gpt_icon":0},{"id":"2432673285","title":"Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2432673285","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432673285?lang=en_us&edition=fundamental","pubTime":"2024-05-02 18:47","pubTimestamp":1714646820,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S.The biotechnology company recorded net income of $722 million, or $6.27 a share, for the first quarter ended March 31, down from $817.8 million, or $7.17 a share, a year earlier. Adjusted earnings were $9.55 a share, below analysts' estimates of $10.17 a share.Revenue ticked down to $3.15 billion from $3.16 billion. Analysts polled by FactSet expected $3.23 billion.Sales of EYLEA in the U.S. decreased in the first quarter compared with the prior-year period, which Regeneron attributed primarily to changing market dynamics that resulted in lower volumes and a lower net selling price.\"We had a strong quarter of EYLEA HD uptake, and we are well positioned to continue our leadership in retinal diseases,\" said Chief Executive Leonard Schleifer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432673337","title":"Regeneron's stock dips after earnings fall short of estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2432673337","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432673337?lang=en_us&edition=fundamental","pubTime":"2024-05-02 18:45","pubTimestamp":1714646700,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals Inc.'s stock  fell 3% early Thursday, after the company's first-quarter earnings fell short of estimates.  The company had net income of $722 million, or $6.27 a share, in the quarter, down 12% from $818 million, or $7.17 a share, in the year-earlier period. Adjusted per-share earnings came to $9.55, below the $10.20 FactSet consensus. Revenue fell 1% to $3.145 billion from $3.162 billion a year ago, also below the $3.225 billion FactSet consensus. Sales of the company's Dupixent treatment for allergic diseases such as atopic dermatitis and asthma rose 24% to $3.08 billion. Sales of Eylea, which treats retinal diseases, fell 2% to $1.402 billion.  The company is now expecting its full-year R&D costs to range from $4.920 billion to $5.170 billion, up from prior guidance of $4.820 billion to $5.070 billion. It expects capex to range from $780 million to$880 million, compared with prior guidance of $850 million to $950 million. The board has approved a new $3.0 b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0836},{"period":"1month","weight":0.0064},{"period":"3month","weight":0.0125},{"period":"6month","weight":0.1715},{"period":"1year","weight":0.2694},{"period":"ytd","weight":0.0896}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.063734},{"month":6,"riseRate":0.393939,"avgChangeRate":0.002817},{"month":7,"riseRate":0.636364,"avgChangeRate":0.053843},{"month":8,"riseRate":0.515152,"avgChangeRate":0.019343},{"month":9,"riseRate":0.484848,"avgChangeRate":0.029068},{"month":10,"riseRate":0.393939,"avgChangeRate":-0.00018},{"month":11,"riseRate":0.545455,"avgChangeRate":0.046018},{"month":12,"riseRate":0.515152,"avgChangeRate":0.048311}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}